Even though tech stocks on average are posting far better gains that health care stocks, a fair number of health care stocks — biotechs specifically — are blowing these tech stocks out of the...
Ford, Trevena, Alibaba, and Snap all posted new 52-week lows Tuesday.
Here 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the remainder of October.
Here is a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the month of October.
Trevena saw its shares make a handy gain to start out Wednesday after the firm announced that the FDA accepted its most recent NDA for Olinvo.
The health care sector was in trouble over the past year, under fire from congressional hearings and politicians on the campaign trail. However things look like they could be different in 2017.
L Brands, Gulfport Energy, TripAdvisor, and Trevena post new 52-week lows on Thursday.
A few biopharma companies have made massive runs on Tuesday morning.
Over the past week, Valeant Pharmaceuticals and a few other biotech companies made impressive runs, due to positive trial results and an FDA meeting.
Trevena charged after the FDA granted a Breakthrough Therapy designation to its lead product candidate for the management of acute pain.
Over the past week, a few biotech companies made absolutely massive runs. Here is information about some of them, as well as recent trading activity and the consensus price target.
Trevena saw its shares continue to climb during Tuesday’s session on news of a positive Phase 2 trial.
Trevena watched its shares soar in Monday’s after-hours session on news of a positive Phase 2 trial.
Thursday's top analyst upgrades, downgrades and initiations include Alibaba, Mobileye, NetApp, Nike, Salesforce.com and Stratasys.
Six IPOs hit the market Friday , and three of them were biotechs. What stands out is that these emerging pharma deals came on the heels of a wildly successful biotech IPO on Thursday.